A Phase 2 interventional study of MT-8554 in Vasomotor Symptoms (VMS), sponsored by Tanabe Pharma America, Inc.. Completed at 53 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-23.
Sponsored by Tanabe Pharma America, Inc. (part of Tanabe Pharma Corporation) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
An open-label, long term extension study of MT-8554 in postmenopausal women experiencing moderate to severe vasomotor symptoms who completed Study MT-8554-A01
Tanabe Pharma America, Inc. is the lead sponsor of 13 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MT-8554
Drug: MT-8554
MT-8554 Oral
Percentage of Subjects With Adverse Events
Time frame: 52 Weeks
Percentage of Subjects With Serious Adverse Events
Time frame: 52 Weeks
Percentage of Subjects With Clinical Laboratory Tests Abnormalities
Hematology, biochemistry, coagulation and urinalysis
Time frame: 52 Weeks
Change in Blood Pressure
Systolic and diastolic blood pressure
Time frame: Baseline and 52 Weeks
Change in Heart Rate
Time frame: Baseline and 52 Weeks
Change in ECG Parameters
PR, QRS, QT and QTc
Time frame: Baseline and 52 Weeks
Change in Endometrial Thickness as Measured by Transvaginal Ultrasound
Time frame: Baseline and 52 Weeks
Percentage of Participants With Endometrial Hyperplasia as Measured by Endometrial Biopsy
Time frame: 52 Weeks
Change in Average Daily Frequency of Moderate to Severe VMS
Subjects were asked to record frequency and severity of VMS in an electronic diary. Severity levels are defined as follows. Mild : Sensation of heat without sweating Moderate : Sensation of heat with sweating, able to continue activity Severe : Sensation of heat with sweating, causing cessation of activity
Time frame: Baseline and 52 Weeks
Change in Average Daily Severity Score of Mild to Severe VMS
Baseline VMS severity score : (1xFmi + 2xFmo + 3xFse)/(Fmi + Fmo + Fse) VMS severity score for a specific week during the open label treatment period :(1xFmi+2xFmo+3xFse)/(Fmi+Fmo+Fse) Fmi, Fmo, and Fse are the daily frequencies of mild, moderate, and severe VMS respectively. The severity score of VMS ranged from 0 (lowest severity) to 3 (highest severity).
Time frame: Baseline and 52 Weeks
| Milestone | MT-8554 |
|---|---|
| Started | 190 |
| Completed | 77 |
| Not completed | 113 |
| Withdrew: Adverse event | 19 |
| Withdrew: Death | 1 |
| Withdrew: Lost to follow-up | 10 |
| Withdrew: Physician decision | 1 |
| Withdrew: Protocol violation | 51 |
| Withdrew: Withdrawal by subject | 23 |
| Withdrew: Other | 8 |
| percentage of subjects | MT-8554 |
|---|---|
| Percentage of Subjects With Adverse Events | 56.7 |
| percentage of subjects | MT-8554 |
|---|---|
| Percentage of Subjects With Serious Adverse Events | 3.2 |
Hematology, biochemistry, coagulation and urinalysis
| percentage of subjects | MT-8554 |
|---|---|
| Percentage of Subjects With Clinical Laboratory Tests Abnormalities | 15.5 |
Systolic and diastolic blood pressure
| mmHg | MT-8554 |
|---|---|
| Systolic Blood Pressure | 1.3 ± 11.36 |
| Diastolic Blood Pressure | -0.4 ± 7.65 |
| beats/min | MT-8554 |
|---|---|
| Change in Heart Rate | 2.6 ± 7.96 |
PR, QRS, QT and QTc
| msec | MT-8554 |
|---|---|
| PR | 0.4 ± 16.34 |
| QRS | -0.2 ± 9.46 |
| QT | -6.8 ± 22.86 |
| QTcF | -0.6 ± 18.60 |
| QTcB | 1.2 ± 19.66 |
| mm | MT-8554 |
|---|---|
| Change in Endometrial Thickness as Measured by Transvaginal Ultrasound | -0.138 ± 1.4765 |
| percentage of subjects | MT-8554 |
|---|---|
| Percentage of Participants With Endometrial Hyperplasia as Measured by Endometrial Biopsy | 0 |
Subjects were asked to record frequency and severity of VMS in an electronic diary. Severity levels are defined as follows. Mild : Sensation of heat without sweating Moderate : Sensation of heat with sweating, able to continue activity Severe : Sensation of heat with sweating, causing cessation of activity
| episodes/day | MT-8554 |
|---|---|
| Change in Average Daily Frequency of Moderate to Severe VMS | -2.71 ± 4.974 |
Baseline VMS severity score : (1xFmi + 2xFmo + 3xFse)/(Fmi + Fmo + Fse) VMS severity score for a specific week during the open label treatment period :(1xFmi+2xFmo+3xFse)/(Fmi+Fmo+Fse) Fmi, Fmo, and Fse are the daily frequencies of mild, moderate, and severe VMS respectively. The severity score of VMS ranged from 0 (lowest severity) to 3 (highest severity).
| units on a scale | MT-8554 |
|---|---|
| Change in Average Daily Severity Score of Mild to Severe VMS | -0.325 ± 0.6804 |
Collected over 52 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MT-8554 | 1/187 (0.5%) | 6/187 (3.2%) | 91/187 (48.7%) |
| Event | MT-8554 |
|---|---|
| DiverticulitisInfections and infestations | 1/187 |
| Road traffic accidentInjury, poisoning and procedural complications | 1/187 |
| Spinal osteoarthritisMusculoskeletal and connective tissue disorders | 1/187 |
| Adrenal adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/187 |
| Invasive breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/187 |
| CystoceleReproductive system and breast disorders | 1/187 |
| RectoceleReproductive system and breast disorders | 1/187 |
| Vaginal prolapseReproductive system and breast disorders | 1/187 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/187 |
| Event | MT-8554 |
|---|---|
| Paraesthesia oralGastrointestinal disorders | 14/187 |
| ParaesthesiaNervous system disorders | 14/187 |
| Upper respiratory tract infectionInfections and infestations | 10/187 |
| Feeling hotGeneral disorders | 9/187 |
| HypoaesthesiaNervous system disorders | 8/187 |
| Urinary tract infectionInfections and infestations | 7/187 |
| Back painMusculoskeletal and connective tissue disorders | 6/187 |
| Hypoaesthesia oralGastrointestinal disorders | 5/187 |
| OverdoseInjury, poisoning and procedural complications | 5/187 |
| Alanine aminotransferase increasedInvestigations | 5/187 |
3 subjects did not take any study medication so these subjects were excluded from the Safety Population.
| Age, Continuous(years) | MT-8554 |
|---|---|
| Mean | 54.6 ± 6.66 |
| Sex: Female, Male(Participants) | MT-8554 |
|---|---|
| Female | 187 |
| Male | 0 |
| Race (NIH/OMB)(Participants) | MT-8554 |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 47 |
| White | 138 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2018 to primary completion in Nov 2019, 18 months.
Results were first posted in Oct 2022, 2 years 10 months after primary completion. A results delay was requested in Nov 2020.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elismetrep